Table 1.
General characteristics of patients in two groups.
| Characteristics | Group 1 (n=68) | Group 2 (n=53) | P value |
|---|---|---|---|
| n (%) | n (%) | ||
| Age (years) | 0.964 | ||
| Median(range) | 48 (18-76) | 47 (23-74) | |
| Sex | 0.667 | ||
| Male | 53 (77.9) | 43 (81.1) | |
| Female | 15 (22.1) | 10 (18.9) | |
| Smoking history | 0.845 | ||
| No | 29 (43.3) | 22 (41.5) | |
| Yes | 38 (56.7) | 31 (58.5) | |
| Histological type | 0.900 | ||
| WHO II | 29 (42.6) | 22 (41.5) | |
| WHO III | 39 (57.4) | 31 (58.5) | |
| T stage | 0.900 | ||
| T1 | 11 (16.2) | 10 (18.9) | |
| T2 | 14 (20.6) | 9 (17.0) | |
| T3 | 22 (32.4) | 20 (37.7) | |
| T4 | 21 (30.9) | 14 (26.4) | |
| N stage | 0.082 | ||
| N0 | 7 (10.3) | 2 (3.8) | |
| N1 | 18 (26.5) | 9 (17.0) | |
| N2 | 21 (30.9) | 28 (52.8) | |
| N3 | 22 (32.4) | 14 (26.4) | |
| Overall stage | 0.653 | ||
| I | 2 (2.9) | 1 (1.9) | |
| II | 6 (8.8) | 2 (3.8) | |
| III | 23 (33.8) | 22 (41.5) | |
| IVA | 37 (54.4) | 28 (52.8) | |
| KPS | 1.000 | ||
| <80 | 3 (4.4) | 2 (3.8) | |
| ≥80 | 65 (95.6) | 51 (96.2) | |
| LDH(U/L) | 0.085 | ||
| <245 | 67 (98.5) | 48 (90.6) | |
| ≥245 | 1 (1.5) | 5 (9.4) | |
| HB (g/L) | 0.327 | ||
| <130 | 9 (13.2) | 11 (20.8) | |
| ≥130 | 59 (86.8) | 42 (79.2) | |
| PLT (×109/L) | 0.432 | ||
| <300 | 59 (88.1) | 44 (83.0) | |
| ≥300 | 8 (11.9) | 9 (17.0) | |
| Treatment pattern | 0.825 | ||
| CCRT | 44 (64.7) | 33 (62.2) | |
| IC+CCRT | 10 (14.7) | 10 (18.9) | |
| RT/IC+RT/CCRT+AC | 14 (20.6) | 10 (18.9) |
WHO II, non-keratinizing differentiated carcinoma; WHO III, non-keratinizing undifferentiated carcinoma; KPS, karnofsky performance status; LDH, lactate dehydrogenase; HB, haemoglobin; PLT, platelet; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiation therapy; AC, adjuvant chemotherapy.